XRAY Is Down 83% After 5 Years. What History Says Now

DENTSPLY SIRONA (XRAY) Just Exited Its Deepest Drawdown Zone in Years

DENTSPLY SIRONA Inc. (XRAY) has officially moved out of the red zone as of May 14, 2026, marking a significant shift in its long-term recovery trajectory. The stock spent 1,769 days in this drawdown cycle, eventually falling 83.4% from its all-time high of $62.91. While the equity remains deeply discounted compared to its historical peaks, our data shows the intensity of the selling pressure is finally beginning to subside.

The transition from the red zone to the red zone in this context represents a specific recovery event within our tracking system. It indicates that while the stock is still in a historic drawdown, the Drawdown Severity Score™ has improved from its most extreme lows. As of May 14, 2026, the Drawdown Severity Score™ for XRAY stands at 15.3. This score categorizes the current movement as a "Historic" event, yet it represents the first meaningful upward momentum in the score in several months.

A Five-Year Decline Meets a Turning Point

The journey to this current price of $10.44 has been exhaustive for long-term shareholders. XRAY has been mired in this specific drawdown for 1,769 days, a duration that far exceeds the typical volatility seen in the dental supplies and equipment sector. To put this in perspective, the average drawdown duration for this stock across its entire trading history is only 61 days. We are currently witnessing a cycle that is nearly 30 times longer than the historical norm for this asset.

The depth of the decline is equally striking. With a current drawdown of -83.4%, the stock has moved well beyond a standard correction. Our data shows that the average max drawdown for XRAY is typically -6.3%. The current move represents a deviation of massive proportions, suggesting that the fundamental narrative surrounding the company has undergone a total repricing since it hit its all-time high.

Historical Context and Comparable Drops

When we look back at the 194 total historical drawdown events recorded for DENTSPLY SIRONA Inc. (XRAY), very few match the scale of the current environment. Our data shows that XRAY has dropped by 50% or more only 2 times in its history. This is a remarkably small sample size, which suggests that the current -83.4% decline is an outlier event that challenges the stock's historical trading patterns.

In the 2 times this has happened previously, the average duration of the comparable drops was 1,658 days. The current cycle of 1,769 days has already surpassed that average, making this the most protracted period of underperformance in the company's recorded history. While the move out of the deepest part of the red zone is a positive data point, the historical data suggests that recoveries from such deep levels are rarely linear and often take years to fully materialize.

Analyzing the Drawdown Severity Score™ Improvement

The Drawdown Severity Score™ of 15.3 is the primary indicator we use to gauge the intensity of a stock's decline relative to its own history and the broader market. A score in the red zone typically indicates that the asset is experiencing a "once-in-a-decade" type of sell-off. For XRAY, the move from a higher (worse) severity score to the current 15.3 signals that the "velocity of despair" has slowed.

Our data shows that when a stock begins to stabilize after a decline of this magnitude, the Drawdown Severity Score™ often leads the price recovery. It measures the exhaustion of sellers. While we do not have specific news headlines as of May 14, 2026, to attribute this shift to a specific corporate action, the technical improvement in the severity score suggests that the market is beginning to find a floor at these valuation levels.

Current Position and the Gap to Recovery

Despite the recent improvement in the Drawdown Severity Score™, DENTSPLY SIRONA Inc. (XRAY) remains in a precarious position. The gap between the current price of $10.44 and the all-time high of $62.91 remains vast. For the stock to move into a "yellow" or "green" zone, it would need to sustain this upward momentum and significantly close the -83.4% gap.

Investors should note that the current price is still hovering near the bottom of this five-year cycle. The transition we are reporting on is a change in internal momentum, not a declaration that the stock has returned to its former growth trajectory. Our data shows that stocks in the red zone often undergo long periods of "basing" where they trade in a tight range as institutional ownership stabilizes.

What to Watch Next

The next milestone for XRAY will be its ability to maintain a Drawdown Severity Score™ below the critical red zone thresholds. If the score begins to climb again, it would indicate that the current recovery was a "false start" and that the stock may be headed for new all-time drawdown lows. Conversely, a continued move toward a score of 10.0 or lower would suggest the recovery is gaining structural integrity.

We will continue to monitor the 1,769-day drawdown clock. Until XRAY makes a significant move back toward its previous highs, it remains one of the most distressed large-cap stocks in our database. The proprietary severity data indicates the worst of the selling may be behind us, but the road to a full recovery remains long.